



DCVMN 23rd ANNUAL GENERAL MEETING

Africa Forum: “Kick the Tyres”

Dr Nicaise Ndembi
Chief Science Advisor
Africa Centres for Disease Control and Prevention

Friday, 21st October 2022

Vision for African vaccine manufacturing

**To ensure Africa has timely access to vaccines to
protect public health security, by establishing a
sustainable vaccine development and manufacturing
ecosystem in Africa**

The AU has set a goal to ensure 60% of the vaccines administered in Africa are locally manufactured and mandated the PAVM to oversee this task

Context




The African Union calls for a **New Public Health Order** aimed at safeguarding the health and economic security of the continent



The first pillar of the New Public Health Order is **expanding manufacturing of vaccines, diagnostics and therapeutics¹**

Ambition to be enabled by the Framework for Action



The African Union has set a goal to **increase vaccine manufacturing on the African continent to meet 60% of the demand by 2040** and mandated the Partnerships for African Vaccine Manufacturing (PAVM) to **develop a Framework for Action to execute this**

1. Other pillars include: Strengthened public health institutions, Strengthened public health workforce, Respectful, action-oriented partnerships

The PAVM was established under the Africa CDC with four broad objectives to guide its operations



PAVM's four broad objectives




Steward a continental strategy that maintains scale and cost-competitiveness of local manufacturing and promotes equity and security for all



Support partnerships to **create a conducive business environment** that will encourage the emergence of a thriving manufacturing base




Play **intermediary and partner role between Member States and the global community of supporters** on an as-needed basis




Communicate updates and serve as the **central source of information for Africa Vx manufacturing**

The PAVM made significant progress since inception crossing many important milestones in 2021

Facilitated the **African Vaccine Manufacturing Summit** which mandated PAVM and set the target ambitions



The PAVM was **approved by AU Executive Council** and will be **presented to AU Assembly of Heads of State** in February 2022



Finalised Draft 1.0 of the FFA that was peer reviewed by independent experts and scientists

12-13 April

May


November

6-7 December


17 December



Operationalised the PAVM, setting up a task force of 7 workstreams consisting >60 members which hosted >30 hours of workshops and >100 hours of working sessions



Hosted a successful **Stakeholder Engagement Event in Kigali** where significant decisions were made on the FFA bold programs




The PAVM has maintained its momentum into the implementation phase of the initiative in 2022

FFA has been endorsed by AU member states at the Heads of State Assembly



Framework for Action officially released to general public




Bold program task-teams reconvened with weekly meetings to drive implementation



Many implementation lead organisations for FFA bold programs **identified**



Project Management Office (PMO) to oversee implementation of FFA **set up**



Market Intelligence and Demand Workshop organized for stakeholders to establish a vaccine procurement architecture for the continent

February 2022

March 2022

June 2022

PAVM developed a continental strategy that outlines diseases, technology platforms and manufacturing value chain steps that Africa needs to prioritise

☐ Vaccine exists ☐ Vaccine does not yet exist

Potential disease prioritization

Prioritized 22 diseases...



Legacy

Diphtheria	Hepatitis B	Measles	Meningococcal
Whooping Cough	Yellow fever	Typhoid fever	
Tetanus	Tuberculosis	Cholera	

Expanding

HPV	Pneumococcal
HIV	COVID-19
Malaria	Rotavirus

Outbreak

Ebola	Influenza
Chikungunya	Lassa fever
Rift valley fever	Disease X

Technology focus

... requiring a breadth of technology platforms...



Traditional

Innovative

Live attenuated	Inactivated virus	Subunit	Virus-like particle	Viral vector	RNA/DNA
-----------------	-------------------	---------	---------------------	--------------	---------

Potential value chain focus

... along the different steps of the value chain



Fill & Finish (F&F)

Fill & finish for all priority vaccines, enabling achievement of local production targets.



Drug Substance (DS)


Expand drug substance mostly in established platforms




R&D

Expand R&D activities to develop new vaccines for Africa, support more efficient manufacturing and improve vaccine characteristics

Partnerships will be key to implementing these bold programs and PAVM welcomes all stakeholders to play a role



PAVM is creating a Capability and Capacity Network model that comprises of educational industrial and regulatory institutions to build talent and capabilities





THANK YOU



LEARN MORE AT

africacdc.org/covid-19

Safeguarding Africa's Health